2nd closing of ongoing Series A
ZURICH, SWITZERLAND – November 18, 2016 – Biovotion Ltd is announcing the second closing of its ongoing CHF10M Series A financing round with the addition of Harmony Medical Inc., a Hong-Kong based investment company, to its shareholder group. The round is led by Swiss Re (Ticker symbol: SREN). Existing investor STMicroelectronics NV (EPA: STM) is participating in the round as well.
Harmony Medical Inc. specialises in global healthcare investments and supports its portfolio companies in accessing the healthcare markets in China, Hong Kong and several other markets in the region. "The addition of Harmony marks another important strategic milestone for Biovotion," said Dr. Andreas Caduff, CEO and founder of Biovotion Ltd. “An aging population and the requirement for significant improvements in reach and quality of the healthcare systems make the Asian markets very attractive for Biovotion’s offering. Harmony Medical has an unparalleled network in the region and will be of great support in our effort to exploit these business opportunities".
Biovotion Ltd is currently preparing the introduction of its clinical-grade wearable monitoring platform in the medical markets in collaboration with leading global commercialization partners.
About Biovotion Ltd
Biovotion Ltd is a leading wearable physiology monitoring company and provides integrated solutions with connected hardware and value-added monitoring services. Biovotion Ltd’s digital health solutions support users in keeping a healthy lifestyle, improve healthcare treatment outcomes, and aiming to reduce cost of health provision. Biovotion Ltd’s management team is internationally recognised for its expertise in wearable monitoring and holds leading know-how and IP in non-invasive physiological monitoring, including vital sign, hydration, and glucose monitoring. Biovotion Ltd’s wearable solutions have been awarded with multiple international, prestigious prizes and high-caliber endorsements, including an XPrize award in late 2014. In December 2015, Biovotion Ltd has been named Europe’s most innovative medical device company by European CEO.
About Swiss Re
The Swiss Re Group is a leading wholesale provider of reinsurance, insurance and other insurance-based forms of risk transfer. Dealing direct and working through brokers, its global client base consists of insurance companies, mid-to-large-sized corporations and public sector clients. From standard products to tailor-made coverage across all lines of business, Swiss Re deploys its capital strength, expertise and innovation power to enable the risk-taking upon which enterprise and progress in society depend. Founded in Zurich, Switzerland, in 1863, Swiss Re serves clients through a network of around 70 offices globally and is rated "AA-" by Standard & Poor's, "Aa3" by Moody's and "A+" by A.M. Best. Registered shares in the Swiss Re Group holding company, Swiss Re Ltd, are listed in accordance with the International Reporting Standard on the SIX Swiss Exchange and trade under the symbol SREN. For more information about Swiss Re Group, please visit: www.swissre.com or follow us on Twitter @SwissRe.